CA2167597A1 - Compositions pharmaceutiques renfermant comme agents actifs, des derives d¨isoflavone ou leurs sels - Google Patents

Compositions pharmaceutiques renfermant comme agents actifs, des derives d¨isoflavone ou leurs sels

Info

Publication number
CA2167597A1
CA2167597A1 CA002167597A CA2167597A CA2167597A1 CA 2167597 A1 CA2167597 A1 CA 2167597A1 CA 002167597 A CA002167597 A CA 002167597A CA 2167597 A CA2167597 A CA 2167597A CA 2167597 A1 CA2167597 A1 CA 2167597A1
Authority
CA
Canada
Prior art keywords
hydrogen
stands
stand
general formula
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002167597A
Other languages
English (en)
Inventor
Mihaly Nogradi
Agnes Gottsegen
Sandor Antus
Janos Strelisky
Borbala Vermes
Andras Wolfner
Adam Major
Tamas Szuts
Istvanne Bendeffy
Tamasne Marmarosi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHINOIN Ltd (SHORT FORM OF CHINOIN PHARMACEUTICAL AND CHEMICAL WORKS CO)
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2167597A1 publication Critical patent/CA2167597A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/38—2,3-Dihydro derivatives, e.g. isoflavanones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

La présente invention se rapporte à des compositions pharmaceutiques contenant comme agent actif des dérivés de l'isoflavone de la formule générale (I), dans laquelle R<1> représente un groupe alkyle C2-18 éventuellement substitué par alcoxyC1-6, hydroxyle, carbalcoxyC1-6, phényle, benzoyle ou un atome halo; phénylalkyle contenant une chaîne alkyle C1-3 éventuellement substituée par un atome halo ou un groupe nitro ou alcényleC2-6; R<2> et R<3> remplacent hydrogène ou alcoxyC1-6; R<4> remplace hydrogène, alkyleC1-6 ou carboxyle; R<5> remplace hydrogène ou alkyleC1-4; R<6> remplace hydrogène ou, si R<5> remplace hydrogène, R<6> peut également remplacer méthyle ou hydroxyméthyle, à condition que, si R<2>, R<3>, R<4>, R<5> et R<6> remplacent hydrogène, R<1> soit différent d'isopropyle, ou un sel de celui-ci. Les compositions pharmaceutiques de l'invention sont préparées à l'aide de procédés connus et sont appropriées au traitement de l'ostéoporose.
CA002167597A 1993-07-20 1994-07-18 Compositions pharmaceutiques renfermant comme agents actifs, des derives d¨isoflavone ou leurs sels Abandoned CA2167597A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU2082/93 1993-07-20
HU9302083A HUT68558A (en) 1993-07-20 1993-07-20 Method for preparing isoflavon derivatives

Publications (1)

Publication Number Publication Date
CA2167597A1 true CA2167597A1 (fr) 1995-02-02

Family

ID=10983803

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002167597A Abandoned CA2167597A1 (fr) 1993-07-20 1994-07-18 Compositions pharmaceutiques renfermant comme agents actifs, des derives d¨isoflavone ou leurs sels
CA002167714A Abandoned CA2167714A1 (fr) 1993-07-20 1994-07-19 Derives de l¨isoflavone

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002167714A Abandoned CA2167714A1 (fr) 1993-07-20 1994-07-19 Derives de l¨isoflavone

Country Status (7)

Country Link
EP (1) EP0710234A1 (fr)
KR (1) KR960703888A (fr)
CN (1) CN1129445A (fr)
AU (1) AU7236794A (fr)
CA (2) CA2167597A1 (fr)
HU (1) HUT68558A (fr)
WO (1) WO1995003293A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087366A (en) * 1996-03-07 2000-07-11 The Trustees Of Columbia University In The City Of New York Use of flavopiridol or a pharmaceutically acceptable salt thereof for inhibiting cell damage or cell death
IT1289154B1 (it) * 1997-01-03 1998-09-29 Chiesi Farma Spa Derivati di isoflavone loro preparazione e loro impiego terapeutico
US6146668A (en) 1997-04-28 2000-11-14 Novogen, Inc. Preparation of isoflavones from legumes
KR20000001793A (ko) 1998-06-13 2000-01-15 이경하 신규한 벤조피란 또는 티오벤조피란 유도체
AUPP868599A0 (en) * 1999-02-15 1999-03-11 Novogen Research Pty Ltd Production of isoflavone derivatives
AUPQ266199A0 (en) 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
KR100408231B1 (ko) * 2000-08-14 2003-12-01 한국 한의학 연구원 골다공증 예방 및 치료용 플라보노이드 유도체
AUPR363301A0 (en) 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
US7468445B2 (en) 2002-08-07 2008-12-23 University Of Mississippi Antigiardial agents and use thereof
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
GB0412768D0 (en) * 2004-06-08 2004-07-07 Novartis Ag Organic compounds
WO2007099432A2 (fr) * 2006-02-28 2007-09-07 Council Of Scientific And Industrial Research composition pharmaceutique pour la prévention/le traitement de troubles osseux et son processus d'élaboration
TWI324514B (en) 2008-02-26 2010-05-11 Univ Kaohsiung Medical Isoflavone derivatives and pharmaceutical compositions comprising the same
CN102964322A (zh) * 2012-12-12 2013-03-13 中国药科大学 异黄酮或类黄酮脂肪醚类衍生物、其制备方法和医药用途
CN108264506B (zh) * 2018-01-17 2021-01-26 中国药科大学 异黄酮衍生物、其制备方法和医药用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6054379A (ja) * 1983-09-05 1985-03-28 Takeda Chem Ind Ltd 新規４ｈ−１−ベンゾピラン−４−オン誘導体，その製法および用途
EP0478558B1 (fr) * 1990-04-06 1994-02-02 CHINOIN Gyògyszer és Vegyészeti Termékek Gyára RT. Procede ameliore de preparation de derives substitues d'isoflavone

Also Published As

Publication number Publication date
AU7236794A (en) 1995-02-20
HUT68558A (en) 1995-06-28
CA2167714A1 (fr) 1995-02-02
CN1129445A (zh) 1996-08-21
EP0710234A1 (fr) 1996-05-08
KR960703888A (ko) 1996-08-31
WO1995003293A1 (fr) 1995-02-02
HU9302083D0 (en) 1993-10-28

Similar Documents

Publication Publication Date Title
CA2167597A1 (fr) Compositions pharmaceutiques renfermant comme agents actifs, des derives d¨isoflavone ou leurs sels
US5716995A (en) Anti-osteopathic composition
JP4550417B2 (ja) プロスタグランジンｅｐ２及び／又はｅｐ４受容体のリガンドとしてのポリアゾリジノン化合物
AU773081B2 (en) Bioavailable composition of natural and synthetic HCA
US4898870A (en) Pyrroloquinoline quinone compounds useful as an enzyme inhibitor
IL133585A0 (en) Soluble prodrugs of paclitaxel
PT1213296E (pt) Derivados de glucopiranosiloxipirazole composicoes medicas que os contem e intermediarios na sua producao
FR2722098A1 (fr) Nouveaux medicaments a base de metro-nidazole ou d&#39;un melange synergetique de metronidazole et de clindamycine
LV12766A (lv) Composition of l-dopa esters
US4309442A (en) Method for controlling fertility in mammals
EP0577356B1 (fr) Composition topique pour la prévention ou le traitement de l&#39;acné vulgaris
WO1991013898A1 (fr) Composes de o6-guanine benzylee, guanosine et de 2&#39;-desoxyguanine ayant une activite d&#39;appauvrissement de o6-alkylguanine-adn alkyltransferase
US5389646A (en) Methods for treatment and prevention of bone loss using 2,3-benzopyrans
De Haan et al. The risk of sensibilization and contact urticaria upon topical application of fumaric acid derivatives
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
Hudgins et al. Cytostatic activity of phenylacetate and derivatives against tumor cells: Correlation with lipophilicity and inhibition of protein prenylation
EP0499882B1 (fr) Compositions pharmaceutiques contenant des dérivés de la N-acétyl-cysteine pour le traitement de la cataracte
CA2438509A1 (fr) Utilisation de derives de cyclohexenone pour la preparation d&#39;un medicament permettant de traiter la dysurie
US4950686A (en) Anti-mycoplasma agent
JP2001516698A (ja) 食餌補足品としての脂肪酸
US20030203974A1 (en) Methods for treating subjects infected with herpes virus or Neisseria gonorrheae
AU7236694A (en) Pharmaceutical compositions containing as active agent isoflavone derivatives or salts thereof
DE60140685D1 (de) Stemzelldifferenzierung induzierende promoter
EP0526502B1 (fr) Agents antimelanomes et de depigmentation en amine phenolique
US4678810A (en) Medical uses of halogenobenzohenone-oxime derivatives

Legal Events

Date Code Title Description
FZDE Dead